Erythropoietin (EPO) is a hormone that stimulates the production of red blood cells, thereby increasing the oxygen-carrying capacity of the blood. While essential for treating anemia, its relevance to healthspan is speculative, based on preclinical data suggesting potential neuroprotective and tissue-reparative effects. However, its use in healthy individuals carries substantial risks that likely outweigh any unproven benefits.
Verdict
High-risk and unproven for healthspan; avoid outside of clinical necessity.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$400 - $2000
Protocol
- Microdosing protocols (e.g., 20-40 IU/kg once weekly) are highly speculative and lack safety data for longevity.
Flags
- Requires a prescription and is a banned performance-enhancing drug in competitive sports.
- Significantly increases risk of blood clots, stroke, heart attack, and pulmonary embolism.
- Can cause or worsen hypertension (high blood pressure).
- Requires regular blood monitoring (hematocrit, hemoglobin) to avoid dangerous blood viscosity.
- May promote tumor growth in certain types of cancers.